查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2013102

脉络膜萎缩症市场：全球产业分析、市场规模、市占率及2026年至2033年预测（依治疗方法、给药途径、病患细分、疾病阶段、最终用户、国家及地区划分）

Choroideremia Market, By Treatment Type, By Route of Administration, By Patient Demographics, By Disease Stage, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 304 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计到 2025 年，脉络膜萎缩市场价值将达到 97.8595 亿美元，并预计从 2026 年到 2033 年将以 4.87% 的复合年增长率成长。

脉络膜视网膜色素变性是一种罕见的遗传性眼科疾病，主要影响男性，会导致视力逐渐丧失。此病初期表现为弱光视力下降，随后逐渐发展为週边视野丧失，最终发展为中心视野丧失，有时甚至会导致失明。根据美国国立卫生研究院 (NIH) 的政府数据，该疾病的发生率约为五万至十万分之一，并占失明病例的一部分。脉络膜视网膜色素变性市场指的是参与开发和销售这种罕见眼科疾病治疗方法（特别是基因疗法等新型治疗方法）的业务。儘管受影响的人数很少，但由于企业对研发的大量投入、新治疗方法的开发以及对能够真正延缓或阻止视力丧失的治疗方法的迫切需求，该市场仍在持续扩张。

脉络膜萎缩市场－市场动态

基因治疗研发日益受到关注

脉络膜视网膜色素变性市场的主要驱动力是基因疗法研发的扩张，而政府的援助和监管激励措施是推动这项扩张的关键。美国国立卫生研究院 (NIH) 透过资助和针对罕见疾病的倡议来推进基因疗法项目，因为罕见疾病的治疗选择往往有限。由于脉络膜视网膜色素变性是由单一基因突变引起的，因此非常适合基因替代疗法，而政府支持的研究已经推动这些治疗方法进入临床试验阶段，为患者带来了显着的益处。百健公司 (Biogen Inc.)、Spark Therapeutics 和 REGENXBIO 公司等企业正在积极研发这些治疗方法。此外，美国食品药物管理局(FDA) 授予了孤儿药资格认定和罕见疾病认定，帮助企业加速研发进程。这反过来又直接刺激了研究活动和市场成长。

脉络膜视网膜色素变性市场－市场区隔分析：

全球脉络膜视网膜萎缩市场按治疗方法、给药途径、患者人口统计特征、疾病进展阶段、最终用户和地区进行细分。

根据治疗方法方式的不同，市场可细分为六个领域：基因疗法、手术介入、药物疗法、症状治疗、细胞疗法和药物疗法。基因疗法在该市场中占据最重要的地位，因为它能够直接修復导致该疾病的CHM基因，而其他疗法（例如药物和手术）只能控制症状，无法阻止视力丧失。这种疾病极为罕见，发生率约五万分之一到十万分之一，因此世界各国政府将其列为罕见疾病，并透过孤儿药计画和研究经费支持其研发。基因疗法的独特之处在于它利用病毒载体（例如AAV）将功能基因导入视网膜细胞，临床试验已证实部分患者的视力得以维持或改善。作为一种针对病因的一次性治疗方法，基因疗法已展现出显着的临床疗效，因此获得了大部分的资金、临床试验和监管关注，使其成为应用最广泛的领域。

从给药途径来看，市场可分为四个领域：视网膜下注射、玻璃体内注射、口服和静脉注射。视网膜下注射预计将在脉络膜萎缩市场中发挥核心作用，因为它能将基因疗法直接递送至病变部位的受损视网膜细胞。政府支持的临床研究表明，脉络膜萎缩的基因疗法主要透过视网膜下注射给药，这已透过腺结合病毒（AAV）的疗法临床试验得到证实，这些治疗方法可直接靶向视网膜色素上皮和感光细胞。科学研究也证实，与其他给药途径相比，视网膜下注射能够实现更精准、更有效的药物递送，从而使目标部位的药物浓度更高。 Spark Therapeutics 和 REGENXBIO Inc. 等公司广泛采用这种方法，这些公司专注于需要直接递送至视网膜的基于 AAV 的疗法。该疗法的关键特点包括标靶基因递送、提高治疗效果以及适用于单剂量治疗，儘管比玻璃体内注射等替代疗法更具侵入性，但仍是应用最广泛的治疗途径。

脉络膜萎缩市场—区域分析

在北美，强大的研究基础和政府对罕见疾病治疗的持续支持预计将推动脉络膜视网膜萎缩症市场显着成长。美国国立卫生研究院 (NIH) 正在资助多个针对遗传性视网膜疾病的基因治疗项目，并为这些项目从早期研究到临床试验提供全程支持。同时，美国食品药物管理局(FDA) 正在授予孤儿药资格，以加速治疗方法的研发。在美国，政府支持的研究，以及 Spark Therapeutics 和 REGENXBIO 等公司的参与，已经将脉络膜视网膜萎缩症的基因治疗推进到人体临床试验阶段，并取得了可衡量的视力改善。欧洲是下一个关键地区，这得益于积极的临床研究和公共医疗体系的参与。在英国，政府主导的临床试验，包括由英国卫生署资助的试验，正在推动视网膜下基因治疗的早期人体试验，并且制定了系统性的罕见疾病政策，以支持正在进行的研究和患者获得治疗。

加拿大脉络膜萎缩市场—国家概况

加拿大是脉络膜视网膜色素变性（CRP）市场的重要国家，这得益于政府强有力的研究支持以及对罕见眼科疾病的明确医疗保健重视。加拿大防​​盲协会等机构的数据显示，加拿大约有21,000人患有遗传性视网膜疾病，其中包括脉络膜视网膜色素变性，这表明加拿大存在一个需要长期照护和治疗的特殊患者群体。此外，加拿大政府支持的临床研究表明，超过68%的此类患者在法律意义上属于视觉障碍者，凸显了沉重的医疗负担以及对有效治疗方法的迫切需求。加拿大在学术和临床领域也拥有强大的实力，例如亚伯达大学等机构在CRP的基因研究和诊断方面做出了贡献。致力于基因疗法的公司和研究团队透过公共医疗保健计划以及与全球生物技术公司的合作获得支持。总而言之，加拿大完善的医疗保健体系、持续的研究活动以及明确的患者群体为新治疗方法的开发和推广提供了稳定且有组织的支撑。

目录

第一章：刺绣市场概览

  • 分析范围
  • 市场估算期

第二章执行摘要

  • 市场区隔
  • 竞争考察

第三章：刺绣产业的主要市场趋势

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 未来市场趋势

第四章：脉络膜绣术产业分析

  • PEST分析
  • 波特五力分析
  • 市场成长前景展望图
  • 管理体制分析

第五章：刺绣市场：地缘政治紧张局势加剧的影响

  • 新冠疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：刺绣的市场状况

  • 2025年脉络膜绣市场占有率分析
  • 主要製造商的细分数据
    • 对现有公司的分析
    • 新兴企业分析

第七章：脉络膜萎缩症市场：依治疗类型划分

  • 概述
    • 基于细分市场的市场份额分析：按治疗类型
    • 基因治疗
    • 手术介入
    • 药物治疗
    • 症状治疗
    • 细胞疗法
    • 药物治疗

第八章：刺绣市场：依管理途径划分

  • 概述
    • 按给药途径分類的市占率分析
    • 视网膜下注射
    • 玻璃体内注射
    • 口服
    • 静脉注射

第九章：氯异症市场：依患者群体细分

  • 概述
    • 细分市场占有率分析：依患者属性划分
    • 儿童患者
    • 成年患者
    • 老年患者

第十章：绿脓病市场：依疾病进展阶段划分

  • 概述
    • 按给药途径分類的市占率分析
    • 初期
    • 中期
    • 晚期

第十一章：刺绣市场：依最终用户划分

  • 概述
    • 基于细分市场的市场份额分析：按最终用户划分
    • 医院
    • 专科眼科诊所
    • 门诊手术中心
    • 研究和学术机构
    • 居家医疗环境

第十二章：刺绣市场：依地区划分

  • 介绍
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 主要製造商：欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 其他欧洲国家
  • 亚太地区
    • 概述
    • 主要製造商：亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 其他亚太国家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 其他拉丁美洲国家
  • 中东和非洲
    • 概述
    • 主要生产商：中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • 其他中东和非洲国家

第十三章：主要供应商分析：Choroideria Industries

  • 竞争基准
    • 竞争对手仪錶板
    • 竞争定位
  • 公司简介
    • MeiraGTx Limited（UK）
    • REGENXBIO（US）
    • GenSight Biologics（France）
    • Editas Medicine（US）
    • Spark Therapeutics（US）
    • Sangamo Therapeutics（US）
    • CRISPR Therapeutics AG（Switzerland）
    • Nanoscope Therapeutics, Inc.（US）
    • 4D Molecular Therapeutics（US）
    • ProQR Therapeutics NV（Netherlands）
    • Horama SA（France）
    • Homology Medicines, Inc.（US）
    • Beacon Therapeutics（US）
    • Eyevensys（Switzerland）
    • Visgenx（US）
    • Atsena Therapeutics Inc.（US）
    • Coave Therapeutics（US）
    • Neurophth Therapeutics（China）
    • Johnson & Johnson Services, Inc.（US）
    • Ocugen, Inc.（US）

第十四章：AnalystView 的全景视图

简介目录
Product Code: ANV6267

Choroideremia Market size was valued at US$ 9,785.95 Million in 2025, expanding at a CAGR of 4.87% from 2026 to 2033.

Choroideremia is a rare inherited eye disease that mainly affects males and slowly causes vision loss. It starts with difficulty seeing in the dark and gradually leads to loss of side vision and eventually central vision, sometimes resulting in blindness. It mainly affects males. According to government data from the U.S. National Institutes of Health, it affects about 1 in 50,000 to 100,000 people and contributes to a portion of blindness cases. The choroideremia market is the business around making and selling treatments for this rare eye disease, especially newer options like gene therapy. Even though very few people have it, the market is still expanding because companies are investing more in research, new treatment methods are being developed, and there is a clear need for treatments that can actually slow down or stop vision loss over time.

Choroideremia Market- Market Dynamics

Increasing Emphasis on Gene Therapy Development

A key factor driving the choroideremia market is the increasing development of gene therapy, backed by government support and regulatory incentives. The National Institutes of Health promotes gene therapy programs for rare diseases through funding and initiatives, as these conditions often have limited treatment options. Since choroideremia is caused by a single gene mutation, it is well suited for gene replacement approaches, and government-supported studies have already pushed these therapies into clinical trials with visible patient benefits. Companies like Biogen Inc., Spark Therapeutics, and REGENXBIO Inc. are actively working on such treatments. In addition, the U.S. Food and Drug Administration offers orphan drug and rare disease designations, helping companies move faster, which directly increases research activity and market growth.

Choroideremia Market- Segmentation Analysis:

The Global Choroideremia Market is segmented on the basis of Treatment Type, Route of Administration, Patient Demographics, Disease Stage, End User, and Region.

The market is split into six segments according to treatment type: Gene Therapy, Surgical Intervention, Pharmacological Treatment, Symptomatic Treatment, Cell Therapy, and Drug Therapy. Gene therapy is the most important part of this market because it directly fixes the main cause of the disease, the damaged CHM gene, while other options, like drugs or surgery, only manage symptoms and cannot stop vision loss. This disease is very rare, affecting roughly 1 in 50,000 to 100,000 people, which is why governments classify it under rare diseases and support development through orphan drug programs and research funding. Gene therapy stands out because it uses viral vectors (like AAV) to deliver a working gene into retinal cells, and clinical trials have already shown maintained or improved vision in some patients. Because it offers a one-time treatment approach, targets the root problem, and shows real clinical results, most funding, trials, and regulatory attention are focused on gene therapy, making it the most widely adopted segment.

The market is structured into four segments in terms of Route of Administration: Subretinal Injection, Intravitreal Injection, Oral Route, and Intravenous Route. The subretinal injection is anticipated to play a central role in the choroideremia market because it delivers gene therapy directly to the damaged retinal cells where the disease occurs. Government-supported clinical research shows that gene therapies for choroideremia are primarily administered through subretinal delivery, as seen in trials using AAV-based treatments that directly target the retinal pigment epithelium and photoreceptors. Scientific studies also confirm that subretinal injection provides more precise and effective delivery compared to other routes, ensuring higher drug concentration at the target site. This approach is widely used by companies such as Spark Therapeutics and REGENXBIO Inc., which focus on AAV-based therapies requiring direct retinal delivery. Key features of this segment include targeted gene transfer, improved treatment effectiveness, and suitability for one-time therapy, which makes it the most widely adopted route despite being more invasive than alternatives like intravitreal injection.

Choroideremia Market- Geographical Insights

North America is forecasted to register meaningful growth of the choroideremia market due to its strong research base and consistent government support for rare disease therapies. The National Institutes of Health funds multiple gene therapy programs for inherited retinal diseases, supporting both early-stage and clinical research, while the U.S. Food and Drug Administration provides orphan drug designations that help speed up treatment development. Government-backed studies in the U.S. have already advanced gene therapy for choroideremia into human trials with measurable vision improvements, supported by companies such as Spark Therapeutics and REGENXBIO Inc. Europe represents the next significant region, supported by active clinical research and public healthcare involvement, where government-backed trials in the United Kingdom, including funding from the UK Department of Health, have contributed to early human studies of subretinal gene therapy, along with structured rare disease policies that support ongoing research and patient access.

Canada Choroideremia Market- Country Insights

Canada represents an important country in the choroideremia market due to steady government-supported research and a clear healthcare focus on rare eye diseases. According to data supported by organizations like Fighting Blindness Canada, around 21,000 Canadians are living with inherited retinal diseases, including choroideremia, showing a defined patient base that requires long-term care and treatment. In addition, government-linked clinical studies in Canada highlight that over 68% of patients with these conditions are legally blind, indicating a serious healthcare burden and the need for effective therapies. The country also has strong academic and clinical involvement, with institutions such as the University of Alberta contributing to genetic research and the diagnosis of choroideremia. Companies and research groups working with gene-based approaches are supported through public healthcare systems and collaborations with global biotech firms. Overall, Canada's structured healthcare system, ongoing research efforts, and clearly identified patient population support continued development and adoption of new treatments in a stable and organized manner.

Choroideremia Market- Competitive Landscape:

The competitive landscape of the choroideremia market is shaped by a group of biotechnology and pharmaceutical companies focusing on gene-based treatments, as there are limited approved options and ongoing clinical development. Key players include Biogen Inc., Spark Therapeutics, REGENXBIO Inc., MeiraGTx Holdings plc, and 4D Molecular Therapeutics, all working on AAV-based gene therapies targeting the underlying genetic cause. Government-supported clinical data show that multiple gene therapy trials for choroideremia have already progressed to Phase I, II, and III stages across the U.S., UK, and other regions, indicating steady development activity. In addition, public research funding from institutions such as the National Institute for Health and Care Research in the UK and similar government bodies supports clinical studies and infrastructure for these trials. The market remains research-driven, with companies focusing on clinical trial advancement, regulatory approvals, and long-term treatment outcomes, as gene therapy continues to be the primary area of development.

Recent Developments:

In October 2025, DelveInsight and other industry pipeline insights highlighted expanding clinical research and multi-modal approaches (gene therapy, gene editing, RNA-based therapies, optogenetics) advancing through preclinical and clinical stages for choroideremia, signaling broadening therapeutic research activity. This trend reflects a gradual shift toward more diverse treatment strategies, with multiple technologies being explored to address the disease from different angles, indicating steady progress in development efforts and a wider scope for future therapeutic options.

In June 2025, the Choroideremia Research Foundation awarded six new global research grants to accelerate vision science and treatment innovation in choroideremia, funding projects including CRISPR-based gene editing and long-term gene therapy follow-up studies. This reflects continued financial and scientific support for advanced research approaches, with a clear focus on improving long-term treatment outcomes and expanding the scope of therapeutic development for the condition.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CHOROIDEREMIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • MeiraGTx Limited (U.K.)
  • REGENXBIO (U.S.)
  • GenSight Biologics (France)
  • Editas Medicine (U.S.)
  • Spark Therapeutics (U.S.)
  • Sangamo Therapeutics (U.S.)
  • CRISPR Therapeutics AG (Switzerland)
  • Nanoscope Therapeutics, Inc. (U.S.)
  • 4D Molecular Therapeutics (U.S.)
  • ProQR Therapeutics N.V. (Netherlands)
  • Horama SA (France)
  • Homology Medicines, Inc. (U.S.)
  • Beacon Therapeutics (U.S.)
  • Eyevensys (Switzerland)
  • Visgenx (U.S.)
  • Atsena Therapeutics Inc. (U.S.)
  • Coave Therapeutics (U.S.)
  • Neurophth Therapeutics (China)
  • Johnson & Johnson Services, Inc. (U.S.)
  • Ocugen, Inc. (U.S.)

GLOBAL CHOROIDEREMIA MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2020 - 2033

  • Gene Therapy
  • Surgical Intervention
  • Pharmacological Treatment
  • Symptomatic Treatment
  • Cell Therapy
  • Drug Therapy

GLOBAL CHOROIDEREMIA MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033

  • Subretinal Injection
  • Intravitreal Injection
  • Oral Route
  • Intravenous Route

GLOBAL CHOROIDEREMIA MARKET, BY PATIENT DEMOGRAPHICS- MARKET ANALYSIS, 2020 - 2033

  • Pediatric Patients
  • Adult Patients
  • Geriatric Patients

GLOBAL CHOROIDEREMIA MARKET, BY DISEASE STAGE- MARKET ANALYSIS, 2020 - 2033

  • Early Stage
  • Mid Stage
  • Late Stage

GLOBAL CHOROIDEREMIA MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033

  • Hospitals
  • Specialty Ophthalmology Clinics
  • Ambulatory Surgical Centers
  • Research & Academic Institutes
  • Homecare Settings

GLOBAL CHOROIDEREMIA MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Choroideremia Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Choroideremia Market Snippet by Treatment Type
    • 2.1.2. Choroideremia Market Snippet by Route of Administration
    • 2.1.3. Choroideremia Market Snippet by Patient Demographics
    • 2.1.4. Choroideremia Market Snippet by Disease Stage
    • 2.1.5. Choroideremia Market Snippet by End User
    • 2.1.6. Choroideremia Market Snippet by Country
    • 2.1.7. Choroideremia Market Snippet by Region
  • 2.2. Competitive Insights

3. Choroideremia Key Market Trends

  • 3.1. Choroideremia Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Choroideremia Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Choroideremia Market Opportunities
  • 3.4. Choroideremia Market Future Trends

4. Choroideremia Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Choroideremia Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Choroideremia Market Landscape

  • 6.1. Choroideremia Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Choroideremia Market - By Treatment Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment Type, 2025 & 2033 (%)
    • 7.1.2. Gene Therapy
    • 7.1.3. Surgical Intervention
    • 7.1.4. Pharmacological Treatment
    • 7.1.5. Symptomatic Treatment
    • 7.1.6. Cell Therapy
    • 7.1.7. Drug Therapy

8. Choroideremia Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
    • 8.1.2. Subretinal Injection
    • 8.1.3. Intravitreal Injection
    • 8.1.4. Oral Route
    • 8.1.5. Intravenous Route

9. Choroideremia Market - By Patient Demographics

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Patient Demographics, 2025 & 2033 (%)
    • 9.1.2. Pediatric Patients
    • 9.1.3. Adult Patients
    • 9.1.4. Geriatric Patients

10. Choroideremia Market - By Disease Stage

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
    • 10.1.2. Early Stage
    • 10.1.3. Mid Stage
    • 10.1.4. Late Stage

11. Choroideremia Market - By End User

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By End User, 2025 & 2033 (%)
    • 11.1.2. Hospitals
    • 11.1.3. Specialty Ophthalmology Clinics
    • 11.1.4. Ambulatory Surgical Centers
    • 11.1.5. Research & Academic Institutes
    • 11.1.6. Homecare Settings

12. Choroideremia Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Choroideremia Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Choroideremia Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.3.18. Rest of Europe
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.18.5. Rest of the Europe Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Choroideremia Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Choroideremia Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Choroideremia Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)

13. Key Vendor Analysis- Choroideremia Industry

  • 13.1. Competitive Benchmarking
    • 13.1.1. Competitive Dashboard
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. MeiraGTx Limited (U.K.)
    • 13.2.2. REGENXBIO (U.S.)
    • 13.2.3. GenSight Biologics (France)
    • 13.2.4. Editas Medicine (U.S.)
    • 13.2.5. Spark Therapeutics (U.S.)
    • 13.2.6. Sangamo Therapeutics (U.S.)
    • 13.2.7. CRISPR Therapeutics AG (Switzerland)
    • 13.2.8. Nanoscope Therapeutics, Inc. (U.S.)
    • 13.2.9. 4D Molecular Therapeutics (U.S.)
    • 13.2.10. ProQR Therapeutics N.V. (Netherlands)
    • 13.2.11. Horama SA (France)
    • 13.2.12. Homology Medicines, Inc. (U.S.)
    • 13.2.13. Beacon Therapeutics (U.S.)
    • 13.2.14. Eyevensys (Switzerland)
    • 13.2.15. Visgenx (U.S.)
    • 13.2.16. Atsena Therapeutics Inc. (U.S.)
    • 13.2.17. Coave Therapeutics (U.S.)
    • 13.2.18. Neurophth Therapeutics (China)
    • 13.2.19. Johnson & Johnson Services, Inc. (U.S.)
    • 13.2.20. Ocugen, Inc. (U.S.)

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us